marginally significantP ≤.09
At the end of the program, participants demonstrated a marginally significant reduction in HbA1c (–0.30%, P ≤.09) and a significant increase in participants reporting good-to-excellent health from baseline (n=19, 39.6%) to posttest (n=28, 58.3%; P ≤.003).